Concepedia

Tibor Keler

TK

Statistics

Publications

100

Citations

10.1K

H-Index

53

Active since

1984

Affiliations

Celldex Therapeutics (United States)(Current)

Memorial Sloan Kettering Cancer Center

Roswell Park Comprehensive Cancer Center

Providence Portland Medical Center

Rockefeller University

Tibor Keler is an author at Celldex Therapeutics (United States) specializing in immunology, life sciences, and oncology.

ORCID

Publications per year

1984–2023

100

Publications

100

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

, , +13

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Marina Caskey, Florian Klein, Julio C. C. Lorenzi et al. · Nature · 2015 · 774 citations

, , +12

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

Marina Caskey, Till Schoofs, Henning Gruell et al. · Nature Medicine · 2017 · 510 citations

, , +14

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Johannes F. Scheid, Joshua A. Horwitz, Yotam Bar‐On et al. · Nature · 2016 · 482 citations

, , +16

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

Kristin M. Sanderson, Ronald Scotland, Peter P. Lee et al. · Journal of Clinical Oncology · 2004 · 433 citations

, , +17

1–5 of 100